LUPIN Ltd - Steady Outlook on Product Development; Maintain ADD
eported revenue grew by 12.6% YoY, led by the India business, which grew by 18.8% YoY, and the Asia-Pacific business, which grew by 30% YoY.
128 Views
Lupin: US and India on Steady Footing, Upgrade to ADD
We upgrade Lupin (LPC) to ADD from REDUCE with a revised TP of INR 2,440 (31x Q3FY27E, up from INR 1,950 at 28x Q1FY27E)
168 Views
Lupin - Launches Critical for Sustenance of Turnaround
Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio.
351 Views
APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin
Mesoblast got FDA approval for its first drug, while Betta Pharma, Celltrion, and Lupin also received some major FDA approvals. Pharma companies...
239 Views
Lupin - Niche Product Drives Earnings Growth
Motilal Oswal's research report onLupin Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with...
349 Views